Immuno-oncology research focuses on harnessing the immune system to combat cancer, aiming to overcome mechanisms of immune evasion and suppression. Key strategies include immune checkpoint inhibitors, adoptive cell therapies (e.g., CAR-T, TCR-T), cancer vaccines, and bispecific antibodies. A significant translational challenge is the lack of preclinical models that accurately mimic the human tumor microenvironment (TME) and its dynamic crosstalk with immune cells. Advanced in vitro models like tumor organoids are essential to bridge this gap.
Conventional 2D cell cultures and animal models often fail to predict outcomes due to their inability to mimic human-specific TME architecture and cellular heterogeneity. The 3D cancer organoid models, derived from patient tissues or engineered cell lines, preserve the genetic, phenotypic, and histological characteristics of the original tumor, supporting the co-culture of malignant cells with various immune cell types (e.g., T cells, NK cells, macrophages). This enables the study of critical processes like immune cell infiltration, activation, exhaustion, and tumor cell killing in a controlled, reproducible, and human-relevant system.
| Types of Organoids | Immune Cell | Co-Culture Method | Drug Test |
| Colorectal Cancer Organoid | CD8+ T cells, Dendritic cells, macrophages | 3D embedded culture in Matrigel domes | Evaluation of immune checkpoint inhibitors and other immunomodulators |
| Liver Cancer Organoid | TILs, CD8+ T cell, PBMCs | Matrigel dome-based 3D co-culture platform | Available for customized therapeutic assessment (e.g., targeted therapies, immunotherapies) |
| Renal Cell Carcinoma Organoid | CD8+ T cell | Submerged Matrigel, Air-liquid interface (ALI), 3D spheroid co-culture systems | Screening of immunotherapeutic agents and combination therapies |
| Lung Cancer Organoid | CD8+ T cell, CD4+ T cell, macrophages | Submerged Matrigel domes or ALI system | Assessment of immunotherapies and adoptive cell therapies (e.g., CAR-T) |
Cancer organoids serve as an in vitro platform bridging basic discovery and application translation in immuno-oncology. They enable the modeling of specific immune responses and the evaluation of therapeutic efficacy in a controlled yet biologically complex setting.
Leveraging deep expertise in 3D cancer model biology and a state-of-the-art translational research platform, Alfa Cytology delivers end-to-end, bespoke immuno-oncology research solutions designed to accelerate the transition from bench to bedside. Our services generate reliable and predictive data, de-risk therapeutic development, and provide actionable insights into novel immunotherapy mechanisms.
Alfa Cytology's service portfolio for immuno-oncology research encompasses the development of a diverse array of tumor organoid models. This includes models derived from various cancer types, multiple biological sources, and utilizing different 3D culture methodologies (e.g., embedded Matrigel, air-liquid interface, microfluidic chips) tailored to specific experimental requirements.
By Disease
By Sources
Alfa Cytology tailors every aspect of our services to your unique research questions. From selecting the most appropriate model system to designing complex co-culture assays and analytical endpoints, we ensure your project objectives are met with scientific rigor.
Organoid Biobanking & Co-culture Systems
Establishment, expansion, and cryopreservation of PDOs, coupled with customized protocols for establishing robust co-cultures with autologous or allogeneic immune cells.
Immune Cell Engineering & Integration
Services encompassing immune cell isolation, activation, genetic modification (e.g., CAR, TCR), and subsequent functional validation in co-culture with matched tumor organoids.
Tumor Microenvironment (TME) Engineering
Custom generation of advanced organoid models incorporating cancer-associated fibroblasts (CAFs), tumor-associated macrophages (TAMs), endothelial cells, and other stromal elements to create a biomimetic immunosuppressive niche.
3D Culture Platform Development
Implementation of specialized culture systems such as air-liquid interface (ALI), microfluidic organ-on-chip devices, or 3D bioprinting to enhance physiological relevance and experimental throughput.
Comprehensive multi-parametric analyses are critical for elucidating the efficacy and mechanisms of immunotherapies. Our integrated approach provides a holistic view of tumor-immune dynamics.
Tumor & Immune Phenotyping
Deep immunophenotyping via flow cytometry or imaging to assess immune cell subsets, activation/exhaustion markers, and tumor antigen/MHC expression.
Functional Cytotoxicity Assays
Quantitative measurement of tumor cell death using real-time live-cell imaging, impedance-based systems, or caspase activity assays.
Secretome Profiling
Multiplex analysis of cytokine/chemokine release (e.g., IFN-γ, TNF-α, IL-2, IL-6, IL-10, TGF-β) to evaluate immune activation status and polarizing signals.
Immune Cell Migration & Infiltration Analysis
Assessment of immune cell trafficking into tumor organoids using time-lapse imaging or endpoint analysis of spatially resolved sections.
Spatial & Histological Analysis
Evaluation of immune cell infiltration, distribution, and spatial relationships within organoids using immunohistochemistry (IHC), immunofluorescence (IF), or multiplex imaging.
Molecular Profiling
Optional downstream genomic, epigenomic, or proteomic analysis to identify transcriptional changes, pathway alterations, and resistance mechanisms in response to therapy.
Alfa Cytology developed a patient-derived colorectal cancer organoid model co-cultured with dendritic cells (DCs) within a three-dimensional matrix to investigate tumor-immune interactions. This physiologically relevant system recapitulated key aspects of the tumor microenvironment, enabling the study of how cancer cells influence the phenotype and function of DCs. Following the co-culture period, a functional allogeneic T cell activation assay was performed to assess the immunostimulatory capacity of the tumor-exposed DCs. Analysis revealed that DCs co-cultured with tumor organoids exhibited a reduced ability to stimulate the proliferation of both CD4+ and CD8+ T cells compared to control DCs cultured alone. These results successfully demonstrated the utility of our advanced 3D co-culture platform for identifying and validating tumor-mediated immunosuppression mechanisms, providing actionable insights for immunotherapy development.
Fig.1 Functional characterization of DCs following co-culture with tumor organoids. The proliferative capacity of T cells was measured after a 6-day co-culture period with sorted DCs that had been pre-exposed to colorectal cancer organoids. Data are presented as mean ± SEM (n=5; *p < 0.05).
Alfa Cytology's specialized immuno-oncology research services empower the discovery and development of next-generation cancer immunotherapies through the application of advanced, human-relevant 3D tumor organoid models. We are committed to delivering precise, actionable data to support your program from target validation and candidate screening to therapy optimization and mechanism research. To discuss how our models can be tailored to advance your specific research objectives, please contact our scientific team for a detailed consultation.
Reference
For research use only.
Alfa Cytology is a preclinical research service provider specializing in tumor organoid development. We provide one-stop services that include tailored 3D cancer models, organoid-based research services, and related products to accelerate the discovery and development of cancer therapeutics.
Copyright © 2026 Alfa Cytology. All rights reserved.